Purple AI Raises KRW 3.3B Series A for Stroke-Triage Medical AI

Purple AI Closes KRW 3.3 Billion Series A

Purple AI (퍼플에이아이), a South Korean medical AI company focused on brain-disease diagnostics, has raised a KRW 3.3 billion Series A round. The funding was announced on 2026-09-28.

Investors

Murex Partners (뮤렉스파트너스) led the round. Additional participants included:

• Korea Credit Guarantee Fund (신용보증기금)
• Torus Partners (토러스파트너스)

What the Company Does

Purple AI develops brain-disease diagnostic software spanning the stroke pathway. Its AI triage products target intracranial hemorrhage, cerebral infarction and brain aneurysm on CT imaging.

The company was founded in October 2024 as a spin-off from SK AX, together with radiology professors from Seoul National University and Ajou University hospitals.

Regulatory and Clinical Position

Purple AI holds US FDA 510(k) clearance and Korea MFDS approval for its flagship hemorrhage-triage product. The company supplies roughly 40 South Korean general hospitals.

On the US side, its validation work includes a 13-site pivotal trial and a research collaboration with Mass General Brigham.

Why It Matters

Stroke triage is a time-sensitive clinical workflow, and CT imaging is typically the first-line modality for distinguishing between hemorrhage and infarction. AI triage tools in this setting are designed to flag critical findings quickly so that care teams can prioritize cases appropriately.

Purple AI's approach covers multiple conditions along the stroke pathway rather than a single indication, and its regulatory clearances in both the United States and South Korea give it a footing in two distinct markets. The company's hospital footprint in South Korea, at roughly 40 general hospitals, provides a commercial base as it pursues US validation.

Funding Stage

The Series A round provides capital following the company's spin-off from SK AX in late 2024. Specific allocation plans for the proceeds were not disclosed in the available information.

Summary

• Company: Purple AI (퍼플에이아이)
• Founded: October 2024, as a spin-off from SK AX with radiology professors from Seoul National University and Ajou University hospitals
• Round: Series A
• Amount: KRW 3.3 billion
• Announced: 2026-09-28
• Lead Investor: Murex Partners (뮤렉스파트너스)
• Other Investors: Korea Credit Guarantee Fund (신용보증기금), Torus Partners (토러스파트너스)
• Focus: AI triage software for intracranial hemorrhage, cerebral infarction and brain aneurysm on CT imaging
• Regulatory: US FDA 510(k) clearance and Korea MFDS approval for flagship hemorrhage-triage product
• Traction: Supplies roughly 40 South Korean general hospitals; US validation includes a 13-site pivotal trial and research collaboration with Mass General Brigham